Management of Hyperprolactinemia in Patients Receiving Antipsychotics

  title={Management of Hyperprolactinemia in Patients Receiving Antipsychotics},
  author={Karen K. Miller},
  journal={CNS Spectrums},
  pages={28 - 32}
  • K. Miller
  • Published 1 August 2004
  • Medicine, Psychology
  • CNS Spectrums
Abstract Hyperprolactinemia is increasingly prevalent in patients with common psychiatric disorders due to increasing prescriptions of antipsychotics, particularly newer atypical neuroleptics, in these patients. However, measurement of prolactin levels is indicated only in symptomatic patients. When hyperprolactinemia is diagnosed, work-up should include exclusion of other causes of hyperprolactinemia, particularly those that might require treatment. Once such causes have been ruled out, a… 

Pharmacological causes of hyperprolactinemia

Hyperprolactinemia has also been documented during conditioning and after autologous blood stem-cell transplantation and during chemotherapy, even though disturbances of prolactin seem to occur less frequently than impairments of the hypothalamus-pituitary-gonad/thyroid axis after intensive treatment and blood marrow transplantation.

Antipsychotic-Induced Hyperprolactinaemia

  • W. InderD. Castle
  • Medicine, Psychology
    The Australian and New Zealand journal of psychiatry
  • 2011
There is a need for a randomised controlled trial of low dose dopamine agonist therapy versus sex steroid replacement to establish the relative safety and efficacy of each approach.

The coexistence of pituitary macroadenoma and schizophrenia – practical therapeutic implications based on the case report and the literature review

The present case report shows that routine imaging tests should be performed as part of the diagnostic procedure in first-episode psychosis and prolactin levels should be measured both before and during therapy, and early and close interdisciplinary cooperation is needed to develop common therapeutic recommendations that could be applied in difficult and non-typical clinical cases.

Menstrual disturbances in puberty.

Integrating machine learning with electronic health record data to facilitate detection of prolactin level and pharmacovigilance signals in olanzapine-treated patients

Risperidone and aripiprazole exhibited the strongest associations with hyperprolactinemia and decreased blood PRL according to the disproportionality analyses, and both were identified as co-administered drugs that influenced PRL levels during OLZ treatment by SHAP analyses.

Antipsychotika und Hyperprolaktinämie: Pathophysiologie, klinische Bedeutung, Abklärung und Therapie

ZusammenfassungHyperprolaktinämie ist eine häufige, vom Endokrinologen und Gynäkologen meist zu wenig beachtete unerwünschte Wirkung herkömmlicher, aber auch vieler neuerer sog. atypischer

Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.

Cabergoline may be useful for the treatment of risperidone-induced hyperprolactinemia in youth; however, further research is needed.

Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study.

Results suggest that low-dose cabergoline treatment of risperidone-induced hyperprolactinemia may be safe and clinically effective in a relevant number of patients.

Risperidone-associated hyperprolactinemia.

  • A. KearnsD. GoffD. HaydenG. Daniels
  • Medicine, Psychology
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2000
Risperidone is a potent inducer of hyperprolactinemia in outpatients with schizophrenia in a community population and the higher and more frequently increased prolactin concentrations caused by ris peridone could adversely affect patient health and compliance.

Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.

Antipsychotics show major differences in their effects on prolactin, and risperidone has clearly the most robust effect.

Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients.

Risperidone treatment, as opposed to olanzapine, for female premenopausal schizophrenia results in hyperprolactinemia and clinically relevant decrease in bone mineral density and bone speed of sound.

Effects of prolactin and estrogen deficiency in amenorrheic bone loss.

Multiple comparisons of clinical variables, serum hormone concentrations, and bone mass demonstrated a significant correlation between bone density and serum dehydroepiandrosterone sulfate levels, which suggests a role for endogenous androgens in the maintenance of premenopausal bone mass.

Dopamine antagonists and the development of breast cancer.

Antipsychotic dopamine antagonist use may confer a small but significant risk of breast cancer, and the possibility of residual confounding should lead to follow-up investigations but not to changes in treatment strategies.

Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women.

Prospective data suggest that higher plasma prolactin levels are associated with an increased risk of breast cancer in postmenopausal women.

The BT

  • J Int Med
  • 2003